Acute bronchopneumonia with Bordetella bronchiseptica bacteremia in an immunocompromised patient with bronchiectasis: A case report and review of the literature
Abstract
Bordetella bronchiseptica rarely causes human disease, and bloodstream infection is exceptional. We describe a 69-year-old man with follicular lymphoma on lenalidomide-rituximab, complicated by hypogammaglobulinemia and bronchiectasis, who developed acute bronchopneumonia with B. bronchiseptica bacteremia. Despite pre-admission oral levofloxacin, he presented with fever and productive cough. Computed tomography of the chest revealed new ground-glass and consolidative opacities. Two aerobic blood-culture bottles yielded slender Gram-negative rods; direct matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) suggested B. bronchiseptica, concordant with subculture. The isolate showed high minimal inhibitory concentrations (MICs) to third-generation cephalosporins but low MICs to piperacillin, carbapenems, aminoglycosides, tetracyclines, and fluoroquinolones. Therapy was changed from ceftriaxone to piperacillin, followed by step-down to oral minocycline, with clinical resolution after a total of 14 days. There was no animal exposure. Because 16S rRNA sequencing alone cannot reliably distinguish classical Bordetella species, we reported the organism as most consistent with B. bronchiseptica based on composite evidence (phenotype, MALDI-TOF MS, 16S). A focused literature review identified few well-documented bacteremia cases, predominantly in immunocompromised hosts, most often with respiratory sources. This case underscores the need to…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Neuroprotective Effects of Epicatechin against Oxidative Stress-Induced Cognitive Impairment: A Systematic Review and Meta-Analysis
- Photochemical behavior of levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.